Business condition attached to the margin of safety
Positive cash generation after stock compensation (operating cash flow exceeding stock-based compensation and capital spending) for several consecutive quarters, with the term loan covenants comfortably met.
Outset Medical makes the Tablo hemodialysis system, a console plus single-use cartridges and services, sold to dialysis providers and hospitals. Revenue was $49.9 million in 2020, $102.6 million in 2021, $115.4 million in 2022 and $130.4 million in 2023, then fell to $113.7 million in 2024 and recovered to $119.5 million in 2025. The company has never produced positive earning power on the measure we use: cash from operations, less the cash effect of working-capital swings, less stock compensation (a real cost we deduct), less the maintenance share of capital spending. On that basis the result per share was about -$103 in 2020 (a partial year after the September 2020 IPO on a very small share count), -$38 in 2021, -$50 in 2022, -$53 in 2023, -$37 in 2024 and -$4.29 in 2025. All amounts are adjusted for the 15-for-1 reverse stock split of March 2025. Cash used in operations improved from $131.4 million in 2023 to $116.3 million in 2024 and $46.3 million in 2025, and the net loss narrowed from $172.8 million to $128.0 million to $81.7 million. That is real progress, but 2025 owner earnings were still about -$65 million, and the company reports an accumulated deficit of $1.2 billion. Note that 2025 per-share figures rest on a much larger share count (about 15.2 million weighted shares versus about 3.5 million in 2024) after the preferred stock converted and new shares were issued, so per-share improvement overstates the improvement in the business. Bear, base and bull cases. We can name and evidence the following facts: a recurring-revenue model (cartridges and services on an installed base of consoles), a declining cash burn, and a gross-margin improvement programme, including moving production to Mexico. What we cannot point to is any signed contract, backlog or track record showing the business reaching positive owner earnings. Management's stated intention to expand gross margins and cut costs is a target, and under our approach targets are not counted as growth or margin expansion. So no earnings stream enters any case, and each case is worth $0 per share: bear $0, base $0, bull $0. Because our method values only the earnings stream and does not subtract debt or add balance-sheet cash on top of it, this leaves value at $0 rather than at the company's cash balance. It is not that the business is proven worthless; it is that nothing we can evidence yet supports a positive value on this measure. The bull case is the one to watch: if the burn keeps falling at the 2025 pace and margins improve as planned, owner earnings could turn positive, but that has not happened. Risks that shape the downside. In January 2025 the company borrowed $100 million under a senior term loan from Perceptive, maturing January 2030 at a floating rate of term SOFR (with a 4.00% floor) plus 8.00%; $101.5 million was outstanding at December 31, 2025. The loan carries covenants including a minimum cash balance and trailing twelve-month revenue targets, and a breach could be an event of default. The company held $172.8 million of cash, restricted cash and short-term investments at year-end 2025, and its 2025 annual report does not contain a going-concern warning; it does state that further financing may be needed and may not be available on favorable terms. Nasdaq had flagged a failure to meet the minimum bid price before the reverse split; the company regained compliance, but the filing notes that a further shortfall within one year of the split would bring a delisting notice. What would make this wrong: sustained positive operating cash flow after stock compensation, which would move value above zero. We have not found a specific fact in the filings that supports that today. Our earlier-style reliance on cash is deliberately excluded, so the company's cash and revenue growth are not counted in our figures. The margin-of-safety price is $0 until the business shows positive cash generation for several consecutive quarters; at that point the analysis would be redone. Ten years of history are not available because the company only went public in 2020; six years (2020 to 2025) are used. Working-capital effects were taken from the receivables, inventory, payables, employee-liability and deferred-revenue lines, which we could reconcile to the cash-flow statement only approximately.